Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Predictive biomarkers of response to immunotherapy in soft tissue sarcoma

Erlinda Gordon • 9 Sep 2022
ESMO 2022
Sarcoma

Erlinda Gordon, MD, Cancer Center of Southern California/Sarcoma Oncology Center, Santa Monica, CA, discusses the absence of predictive biomarkers of response to immunotherapy in patients with soft tissue sarcoma. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Erlinda Gordon

0:45
Immunotherapy for sarcoma
Erlinda Gordon • 9 Oct 2022
3:30
Rationale of using immunotherapy for advanced leiomyosarcoma
Erlinda Gordon • 9 Sep 2022
1:47
Cost and immune-related adverse events in patients with sarcoma treated with immunotherapy
Erlinda Gordon • 9 Sep 2022
1:06
Results of a Phase I/II study of ipi, nivo and trabectedin as 1L therapy for advanced LMS
Erlinda Gordon • 9 Sep 2022

Related Videos

0:51
Enhanced NK-cells in stage 4 sarcoma treatment
Vaishali Kumar • 8 Apr 2024
1:12
Predictive biomarkers for checkpoint inhibitors in sarcomas
Nadia Omelchenko • 8 Apr 2024
1:26
SAINT and LINNOVATE: combining ICIs and chemotherapy in advanced STC
Nadia Omelchenko • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals